BioLife Solutions (BLFS)
(Delayed Data from NSDQ)
$18.46 USD
+0.36 (1.99%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $18.41 -0.05 (-0.27%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth D Momentum C VGM
Income Statements
Fiscal Year end for BioLife Solutions, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 143 | 162 | 119 | 48 | 27 |
Cost Of Goods | 97 | 108 | 82 | 21 | 9 |
Gross Profit | 47 | 54 | 37 | 27 | 19 |
Selling & Adminstrative & Depr. & Amort Expenses | 118 | 199 | 71 | 33 | 19 |
Income After Depreciation & Amortization | -71 | -146 | -34 | -6 | 0 |
Non-Operating Income | 5 | 1 | 6 | 5 | -3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -66 | -145 | -28 | -1 | -3 |
Income Taxes | 0 | -5 | -20 | -3 | -2 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -66 | -140 | -8 | 3 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -66 | -140 | -8 | 3 | -2 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -59 | -129 | -21 | -1 | 2 |
Depreciation & Amortization (Cash Flow) | 12 | 16 | 13 | 5 | 2 |
Income After Depreciation & Amortization | -71 | -146 | -34 | -6 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 43.72 | 42.48 | 38.50 | 27.31 | 22.03 |
Diluted EPS Before Non-Recurring Items | -1.04 | -0.69 | -0.55 | 0.01 | 0.08 |
Diluted Net EPS (GAAP) | -1.52 | -3.29 | -0.20 | -0.03 | -0.09 |
Fiscal Year end for BioLife Solutions, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 32.73 | 33.33 | 39.51 | 37.70 | 44.26 |
Cost Of Goods | 23.48 | 21.68 | 27.70 | 23.66 | 30.29 |
Gross Profit | 9.25 | 11.65 | 11.81 | 14.04 | 13.97 |
SG&A, R&D, and Dept/Amort Expenses | 22.41 | 40.43 | 27.09 | 27.64 | 64.21 |
Income After SG&A, R&D, and Dept/Amort Expenses | -13.16 | -28.78 | -15.28 | -13.60 | -50.24 |
Non-Operating Income | 0.24 | 0.24 | 5.51 | 0.39 | -0.24 |
Interest Expense | -1.31 | 0.48 | 0.42 | 0.41 | -0.17 |
Pretax Income | -13.43 | -29.02 | -10.19 | -13.62 | -50.31 |
Income Taxes | -0.04 | 0.12 | 0.01 | 0.09 | -0.08 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -13.38 | -29.13 | -10.20 | -13.71 | -50.23 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -13.38 | -29.13 | -10.20 | -13.71 | -50.23 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 44.82 | 43.57 | 43.44 | 43.03 | 42.79 |
Diluted EPS Before Non-Recurring Items | -0.22 | -0.34 | -0.24 | -0.27 | -0.19 |
Diluted Net EPS (GAAP) | -0.30 | -0.67 | -0.23 | -0.32 | -1.18 |